Your session is about to expire
← Back to Search
Intraocular Lens
Clinical Trial to Evaluate the Model SC9 IOL Compared to the Model LI61SE IOL (Bausch & Lomb)
N/A
Waitlist Available
Research Sponsored by CORD, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new eye lens called Model SC9 to see if it helps people see better up close and at middle distances compared to a standard lens. It involves patients who need lens implants and will follow them for several years.
Eligible Conditions
- Cataract
- Pseudoaphakia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Improvement in Visual Acuity Measurements using the LogMar Scale
Secondary study objectives
Defocus testing in 0.5D increments from -0.5 to -5.00D
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Model SC9Experimental Treatment1 Intervention
Investigational IOL
Group II: Model LI61SEActive Control1 Intervention
FDA Approved IOL
Find a Location
Who is running the clinical trial?
CORD, LLCLead Sponsor
J Stuart Cumming, M.D.Study ChairCORD, LLC
John Hovanesian, M.D.Study ChairCORD, LLC
2 Previous Clinical Trials
448 Total Patients Enrolled